EBC-46
Blood Markers, Doctor Reactions, and the Blushwood Reports That Stand Out
When doctors start looking up Blushwood berry themselves after reviewing patient blood work, the anecdotal becomes harder to ignore.
Marcus Webb
Science writer and independent researcher specialising in natural compound pharmacology and translational oncology. Tracking EBC-46 (tigilanol tiglate) and Blushwood berry extract since 2019.
EBC-46
The Unmapped Phytochemistry of the Blushwood Berry: What Else Is in There?
Tigilanol tiglate is the headline compound — but the full phytochemical profile of Fontainea picrosperma remains largely uncharacterised, and that may matter enormously.
EBC-46
Biomarker Endpoints in EBC-46 Trials: Measuring What Matters Beyond Tumour Shrinkage
Modern EBC-46 trials track immune activation markers, vascular disruption signatures, and PKC pathway biomarkers — not just tumour volume.
EBC-46
Blood Markers, Doctor Reactions, and the Blushwood Reports That Demand Scientific Attention
From blood clot resolution observed by physicians to eyes clearing post-sepsis — verified buyer accounts involving objective clinical data represent a signal science cannot afford to ignore.
EBC-46
Indoor Cultivation of Fontainea picrosperma: What Growers Around the World Have Learned
Fontainea picrosperma grows wild only in north Queensland's rainforests, but controlled indoor cultivation has succeeded in Australia and Asia — here is what growers have discovered.
EBC-46
Tigilanol Tiglate and Checkpoint Inhibitors: The Synergy Hypothesis and Emerging Trials
EBC-46's ability to convert immunologically cold tumours into hot ones makes it a compelling partner for checkpoint blockade — here is the biology and the trial rationale.
EBC-46
PKC Isoforms and Mitochondrial Energy Metabolism: How EBC-46 Reaches Beyond the Tumour
EBC-46 targets PKC isoforms that regulate mitochondrial function and energy metabolism — a biological dimension that extends the compound's relevance well beyond oncology.
EBC-46
Compassionate Use and Expanded Access for Tigilanol Tiglate: What Patients Need to Know
Expanded access programmes offer a potential pathway for cancer patients to receive tigilanol tiglate outside clinical trials — here is how the regulatory process works.
EBC-46
Energy, Inflammation, and Systemic Wellbeing: What Verified Blushwood Users Are Reporting
Independently collected accounts from verified blushwood extract users reveal a consistent pattern of inflammation reduction, improved energy, and systemic wellbeing changes — a signal the research community should investigate.
EBC-46
Tigilanol Tiglate and Checkpoint Inhibitors: Why Researchers Are Exploring the Combination
EBC-46 lights the immune fire with acute local tumour antigen release. Checkpoint inhibitors remove the suppressors trying to extinguish it. The combination rationale is mechanistically sound.
EBC-46
PKC Isoforms and Mitochondrial Energy Metabolism: EBC-46 Beyond the Tumour
The same PKC isoforms EBC-46 activates for anti-tumour effect also regulate mitochondrial membrane dynamics and cellular energy production — a scientifically rich area still awaiting systematic study.
EBC-46
Indoor Cultivation of Fontainea picrosperma: What Growers Around the World Have Learned
Fontainea picrosperma is native to a narrow strip of Far North Queensland rainforest, but dedicated cultivators in indoor environments have successfully grown it far beyond those boundaries.